Aileron Therapeutics (ALRN) News Today

$2.32

+0.14 (+6.42%)

(As of 12/8/2023 ET)

Today's Range: $2.11
▼
$2.43
50-Day Range: $1.16
▼
$2.50
52-Week Range: $1.01
▼
$3.30

Volume: 26,555 shs
Average Volume: 38,834 shs
Market Capitalization: $10.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Source

Source	Headline
	Head to Head Contrast: Aileron Therapeutics (NASDAQ:ALRN) versus TherapeuticsMD (NASDAQ:TXMD) americanbankingnews.com - December 8 at 2:18 AM
	Aileron Therapeutics (NASDAQ:ALRN) Raised to Buy at LADENBURG THALM/SH SH americanbankingnews.com - December 4 at 2:02 AM
	Aileron Therapeutics upgraded to Buy from Neutral at Ladenburg realmoney.thestreet.com - December 1 at 3:46 PM
	Aileron Therapeutics upgraded to Buy at Ladenburg after Lung Therapeutics deal realmoney.thestreet.com - December 1 at 3:46 PM
	Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Up 1,879.5% in November americanbankingnews.com - November 29 at 2:12 AM
	Aileron Therapeutics Director Awarded $6K Worth of Stock Options benzinga.com - November 5 at 3:03 PM
	Aileron gains after all-stock deal to acquire Lung Therapeutics msn.com - November 1 at 3:15 PM
	Aileron Therapeutics Announces Acquisition of Lung Therapeutics finance.yahoo.com - October 31 at 5:03 PM
	Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now finance.yahoo.com - April 4 at 1:28 PM
	Aileron Therapeutics, Inc. (ALRN) finance.yahoo.com - March 22 at 8:03 AM
	Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now finance.yahoo.com - March 14 at 6:11 PM
	Looking Into Aileron Therapeutics's Recent Short Interest msn.com - March 3 at 6:51 PM
	JonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN) markets.businessinsider.com - February 23 at 8:54 AM
	Cancer drugmaker down to 3 employees after trial failure finance.yahoo.com - February 22 at 5:26 PM
	U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.06% msn.com - February 21 at 5:59 PM
	Aileron off 38% on plans to explore sale after setback for cancer candidate seekingalpha.com - February 21 at 5:59 PM
	Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall finance.yahoo.com - February 21 at 5:59 PM
	Aileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924 markets.businessinsider.com - February 21 at 12:59 PM
	Aileron Therapeutics Shares Slide to New Low on Lead Drug Failure >ALRN marketwatch.com - February 21 at 12:59 PM
	Aileron Exploring Options After ALRN-6924 Study Failure >ALRN marketwatch.com - February 21 at 12:59 PM
	marketbeat.com - February 21 at 8:29 AM
	alrn.a - \| Stock Price & Latest News \| Reuters reuters.com - January 17 at 1:37 PM
	What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock msn.com - December 29 at 1:22 PM
	Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements finance.yahoo.com - November 30 at 8:00 AM
	Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now finance.yahoo.com - November 24 at 1:38 PM
	Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Increase in Short Interest marketbeat.com - November 13 at 5:10 AM
	Aileron Therapeutics, Inc.: Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split finanznachrichten.de - November 10 at 5:52 PM
	Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split finance.yahoo.com - November 10 at 5:51 PM
	Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade finance.yahoo.com - November 4 at 3:30 PM
	Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights technews.tmcnet.com - November 1 at 5:55 PM
	Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights finance.yahoo.com - November 1 at 5:55 PM
	Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference finance.yahoo.com - October 26 at 8:45 AM
	Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022 finance.yahoo.com - September 30 at 1:11 PM
	Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference finance.yahoo.com - September 22 at 11:20 AM
	Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference finance.yahoo.com - September 6 at 11:48 AM
	Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights finance.yahoo.com - August 16 at 8:23 AM
	Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights finance.yahoo.com - August 16 at 8:23 AM
	Aileron slips 12% after announcing changes to breast cancer trial design seekingalpha.com - August 1 at 7:01 PM
	Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer finance.yahoo.com - August 1 at 9:01 AM
	Aileron Therapeutics (NASDAQ:ALRN), Short Interest Report benzinga.com - July 5 at 9:45 PM
	Aileron Therapeutics (NASDAQ:ALRN), Analyst Ratings, Price Targets, Predictions benzinga.com - July 5 at 9:45 PM
	Aileron Therapeutics Shares Down After Lung Cancer Data marketwatch.com - July 1 at 2:59 AM
	Aileron Therapeutics Announces Interim Data from Phase 1b tmcnet.com - June 29 at 3:54 PM
	Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting finance.yahoo.com - June 29 at 3:54 PM
	Aileron drug fails to beat placebo in reducing chemo toxicities in lung cancer patients in trial seekingalpha.com - June 29 at 7:44 AM
	Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer finance.yahoo.com - June 29 at 7:44 AM
	Aileron begins dosing in phase 1b trial of ALRN-6924 to prevent toxicities due to chemotherapy seekingalpha.com - May 19 at 4:14 PM
	Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer finance.yahoo.com - May 19 at 4:14 PM
	Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference finance.yahoo.com - May 17 at 12:05 PM
	Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 finance.yahoo.com - May 13 at 6:57 PM

Get Aileron Therapeutics News Delivered to You Automatically

ALRN Media Mentions By Week

ALRN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALRN
News Sentiment
▼
0.40

0.51
▲
Average
Medical
News Sentiment

ALRN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALRN Articles
This Week
▼
2

0
▲
ALRN Articles
Average Week

Get Aileron Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:ALRN) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aileron Therapeutics (ALRN) News Today

ALRN Media Mentions By Week

ALRN Media Sentiment

ALRN News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info